Skip to search formSkip to main contentSkip to account menu

Phosphodiesterase 3 Inhibitor [EPC]

Known as: Phosphodiesterase 3 Inhibitor, Phosphodiesterase III Inhibitor 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Despite the availability of effective antiulcer medications, their suboptimal safety profile ignites the search for alternative… 
2019
2019
BACKGROUND Cilostazol, a phosphodiesterase 3 inhibitor (PDE3I), is a platelet aggregation inhibitor and vasodilator that is… 
Review
2016
Review
2016
Phosphodiesterase 3 inhibitors have been used successfully in pediatric patients with acute or chronic myocardial dysfunction… 
Review
2015
Review
2015
OBJECTIVE: To assess the efficacy and safety of cilostazol on the progression and regression of symptomatic intracranial artery… 
2008
2008
BACKGROUND Cilostazol, a phosphodiesterase 3 inhibitor, is an antiplatelet drug that is widely used for preventing cardiovascular… 
Highly Cited
1999
Highly Cited
1999
The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the… 
1996
1996
1 This study was designed to investigate the role of rat phosphodiesterase 3 (RPDE3) in regulation of liver metabolism in sepsis…